Merck scores high in race for cholesterol drug

Merck is reporting success in its Phase III trial of a new cholesterol drug that combines a known ingredient with a new one that reduces the risk of an uncomfortable and common side effect. Cordaptive--which has been submitted for FDA approval--uses an extended-release form of niacin with another therapy that has significantly reduced the number of times patients experience "flushing," a reddening of the skin that is associated with a burning sensation. By week 24 in the study, patients taking Cordaptive reported one incident of flushing per month on average compared to one incident per week for patients taking niacin alone. Not surprisingly, the groups reported similar levels of cholesterol. Abbott, meanwhile, is advancing its own new version of Niaspan, which also is intended to reduce the number of incidences of flushing. The FDA is expected to make a decision on Cordaptive in the second quarter of '08.

- see the release
- read more on the data from MarketWatch
-
and here's the analysis from the Wall Street Journal

Related Articles:
Merck to delay filing on new cholesterol drug. Report
Pathway found to raise "good" cholesterol. Report
Penn researchers report success in cholesterol control. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.